Drug Profile
NSI 189
Alternative Names: NSI-189; NSI-189 - Neuralstem; NSI-189 phosphateLatest Information Update: 28 Sep 2022
Price :
$50
*
At a glance
- Originator Neuralstem
- Developer Palisade Bio; University of California, San Diego
- Class Antidepressants; Antihyperglycaemics; Neuroprotectants; Nootropics; Piperazines; Pyridines; Small molecules; Vascular disorder therapies
- Mechanism of Action Neurogenesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Major depressive disorder
- No development reported Alzheimer's disease; Angelman syndrome; Brain injuries; Cognition disorders; Diabetic neuropathies; Neurodegenerative disorders; Post-traumatic stress disorders; Stroke; Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for preclinical development in Stroke in USA
- 28 Aug 2022 No recent reports of development identified for preclinical development in Cognition-disorders in USA (PO)
- 28 Aug 2022 No recent reports of development identified for preclinical development in Type-1 diabetes mellitus in USA